Short Interest In XOMA Falls 31.6%

The most recent short interest data has been released by the NASDAQ for the 10/15/2013 settlement date, which shows a 3,106,471 share decrease in total short interest for XOMA Corp ( XOMA), to 6,720,783, a decrease of 31.61% since 09/30/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for XOMA at the 10/15/2013 settlement increased to 1,933,015, as compared to 665,909 at the 09/30/2013 report. That brought "days to cover" down to 3.48, a 76.44% decrease from the 14.76 days to cover calculated at the previous short interest data release.

START SLIDESHOW:
The 10 Most Shorted Stocks of the Dow »

The below chart shows the historical "days to cover" for XOMA at previous short interest release dates:

Loading+chart++2013+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where XOMA had been shorted as a hedge.

The chart below shows the one year performance of XOMA shares, versus its 200 day moving average. Looking at this chart, XOMA's low point in its 52 week range is $2.37 per share, with $5.54 as the 52 week high point — that compares with a last trade of $4.72.

If you liked this article you might like

XOMA (XOMA) Weak On High Volume

Xoma Stock Soaring on Q4 Earnings Beat

Xoma Stock Surges in After-Hours Trading on Q4 Results

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million